
Omnicell, Inc.
- Jurisdiction
United States - LEI
5493008RH0GTKHHPZI77 - ISIN
US68213N1090 (OMCL )- Sectors
Scores
- Fair value (Benjamin Graham formula)
-
€33.29 25.1% undervalued - Financial strength (Piotroski F-Value)
-
7
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
5
/ 7
Profile
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. Read full profile
Fundamentals
- Net revenue
€980.49M - Gross margin
43.7% - EBIT
€13.19M - EBIT margin
1.3% - Net income
€19.69M - Net margin
2.0%
Statement period: - (published )
Estimates
Fiscal Year | Net revenue | Net income |
---|---|---|
|
| |
|
| |
N/A | N/A |
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions
Earnings Calls
Investor transactions
Name | Shares | Value | Last change | Change type |
---|---|---|---|---|
Peter Brown |
|
|
|
Sell |
Earnings Calls
Latest earnings call: May 2, 2024 (Q1 2024)